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Acute myeloid leukemia (AML) is an aggressive malignancy of haematopoietic stem cells driven by a 
well-defined set of somatic mutations
1, 2
. Identifying the mutations driving individual cases is 
important for assigning the patient to a recognized WHO category, establishing prognostic risk and 
tailoring post-consolidation therapy
3
. As a result, AML research and diagnostic laboratories apply 
diverse methodologies to detect important mutations and many are introducing next generation 
sequencing approaches to study extended panels of genes in order to refine genomic classification 
and prognostic category
1
. Besides the implications of these developments on costs, expertise and 
reliance on commercial providers, they also do not capture gene expression data, which have 
independent prognostic value that cannot be inferred from somatic mutation profiles. The ability to 
detect AML gene mutations as well as gene expression profiles from a single assay, could provide a 
holistic tool that accelerates research, simplifies diagnostic work-up and helps develop integrated 
algorithms to refine individual patient prognosis. Here, we show that AML RNA sequencing (RNA-seq) 
data can be used to reliably detect all types of clinically important mutations and develop a bespoke 
fast and easy-to-use software (RNAmut) for this purpose that can be readily used by 
teams/laboratories without in-house bioinformatic expertise.  
 
We focused on detection of mutations in 33 genes that are relevant to AML classification and 
prognosis (Table 1) and designed the software pipeline to operate in 3 stages: read alignment, 
mutation detection and an additional oncogenicity filter (Figure 1A). To ensure fast alignment of 
RNA-seq reads, we indexed all possible 10-mer sequences from our target genes into a look-up table 
(hash function) that maps the 10-mers to their locations on the 33 genes (Supplementary Figure 1A). 
We used 10-mers (instead of 9-mers or 11-mers and etc) for optimal balance between speed and 
memory requirements (Supplementary Table 1). To align RNA-seq reads, the sequence of each read 
is divided into consecutive 10-mers and each 10-mer is mapped to genic locus/loci using the pre-
built look-up table. By examining all 10-mers in a read, RNAmut computes whether the read is 
perfectly aligned (Type A), aligned with mismatches (Type M) or not aligned (Type N, Supplementary 
Figure 1B). M-type reads are used to detect substitutions and small indels (Figure 1B). To detect 
tandem duplications, RNAmut uses the subset of N-type reads for which their 5’ end is mapped 
downstream to their 3’ end, to compute the location of the duplicated region (Figure 1C). Gene 
fusions are detected through two independent pieces of evidence: first, reads spanning the 
breakpoint (i.e. chimeric reads) are extracted from the N-type reads and used to report the location 
of the breakpoint (Figure 1D). Secondly, fusion genes can also be identified from paired-end RNA-seq 
reads when each of the two paired reads aligned to a different fusion partner (Figure 1E). All 
mutations covered by ≥ 3 unique reads are reported and these are then optionally parsing through 
an oncogenicity filter applying the criteria used by the largest AML sequencing study published so 
far
1
 (Supplementary Table 2), which could be especially useful for diagnosticians. Full details of the 
RNAmut pipeline are given in supplementary materials. To benchmark read mapping, we compared 
RNAmut’s alignment with commonly used read aligners
4-6
. Our alignment showed very good 
agreement with panel-restricted alignments by BWA (Supplementary Figure 12A, B) and Salmon 
(Supplementary Figure 14), and global alignment by STAR (Supplementary Figure 13), for all of which 
both Pearson correlation and gradient were very close to 1. 
 
To test the performance of our RNAmut, we analyzed 151 RNA-seq datasets from AML bone marrow 
samples generated by the Cancer Genome Atlas (TCGA)
4
 and detected 40 NPM1 samples, 37 FLT3-
ITD, 35 DNMT3A, 17 IDH2, 13 IDH1, 17 RUNX1, 17 CEBPA, 13 TP53, 13 TET2, 10 FLT3 TKD, 7 MLL-PTD, 
11 WT1, 3 ASXL1, 1 BCOR, 12 SRSF2, 3 SF3B1 and 7 U2AF1 mutations, along with 15 PML-RARA, 10 
MYH11-CBFB, 7 RUNX1-RUNX1T1, 3 BCR-ABL1, 3 NUP98-NSD1 fusions and 8 KMT2A (MLL1) fusions 
with various partners (Supplementary Figure 4A, Supplementary data). Notably RNAmut accurately 
detects the lengths and positions of duplicated regions of FLT3-ITD (Supplementary data, 
Supplementary Figure 8A, B) while also reporting the number of mutated and WT reads and allelic 
frequencies (Supplementary Figure 8C). To assess the accuracy of our software, we compared our 
results with the mutations detected in these samples by Ley et al
2
. Our software detected 289 of the 
291 reported mutations (Figure 2). The two cases that we failed to detect were an IDH1 R132C in 
TCGA-AB-2984 and an MLL-PTD exon2-8 in TCGA-AB-2977. IDH1 R132C was missed due to the 
gene’s low expression in this sample: only 5 good quality reads covered R132 of which only 1 was 
mutated and thus does not meet the minimum of 3 mutant reads required by RNAmut 
(Supplementary Figure 18). To examine the missed MLL-PTD, we constructed the nucleotide 
sequence of the reported exon8-exon2 junction and found no RNA-seq reads reporting such a 
junction, indicating this may have been an annotation error. Moreover, our software identified 29 
samples with mutations that were not reported by Ley et al. (Figure 2). For all these samples, we 
found evidence at the level of RNA and, where available, also DNA (8 samples with whole exome 
sequencing data) to show that they are indeed true positives (Supplementary Figure 19, 20, 
Supplementary Table 4). To further demonstrate the robustness of RNAmut, we tested its 
performance on the RNA-seq data from two other sources:  i) a set of 164 myelodysplastic syndrome 
(MDS) patients
7, 8
 and ii) 437 AML patients studied by the Leucegene consortium
9-12
, both derived 
from bone marrow samples. For the MDS samples, RNAmut detected all panel-gene mutations 
identified through targeted DNA sequencing by the authors (Supplementary Figure 5), as well as 34 
mutations that were not (Supplementary Figure 7). For Leucegene where mutation data are not 
available on a per sample basis, RNAmut detected similar landscapes of mutations overall 
(Supplementary Figure 4B, 6) including all 27 instances of an NPM1 mutation reported in one of the 
consortium’s publications
11
.  
 
To validate our method, we first checked and confirmed that all exon sequences of the 33 panel 
genes are unique in the transcriptome, ruling out the possibility that RNA fragment from non-panel 
genes are mistakenly aligned to the panel (Supplementary Figures 9-11). To benchmark mutation 
calling, we compared RNAmut with commonly used mutation callers. Our VAF calculation agreed 
very closely with Samtools
13
 for substitutions (Supplementary Figure 15A) and with Varscan
14
 for 
both substitutions (Supplementary Figure 15B) and indels (Supplementary Figure 15C). Furthermore, 
RNAmut detected all gene fusions identified by FuSeq
15
 and displayed better sensitivity for detection 
of MLL fusions (Supplementary Table 3). Finally, we also compared the VAFs detected in RNA-seq 
with the ones detected in whole exome DNA sequencing data and observed a good correlation for 
most substitutions (Supplementary Figure 16). Nonsense mutations in DNMT3A (n=3) and TP53 (n=1) 
had lower RNA than DNA VAFs, possibly due to nonsense-mediated decay (NMD). Nevertheless, a 
scan of all gain-of-stop codon mutations showed that transcripts potentially subjected to NMD were 
within detectable levels in AML RNA-seq datasets (Supplementary Figure 17). 
 
Whilst somatic mutation detection from RNA-seq data is not a novel concept
16
, existing software 
packages are designed for whole-transcriptome detection, which requires significantly larger 
memory and long computation time
17
. Also, the lack of integrated pipelines demands intensive 
scripting and manual adjustment of parameters. Moreover, most existing packages are restricted to 
the UNIX system, which excludes the Windows user base and with it, most laboratories without in-
house bioinformatic expertise. In this study, we present RNAmut, a fast, memory efficient and 
platform-independent software, which can run on personal computers including laptops and takes 
less than 30 minutes to detect all types of mutations affecting the selected 33 AML genes, from a 
typical RNA-seq dataset of 100 million paired-end reads (Supplementary Table 1). RNAmut can be 
easily extended to other malignancies by adding or removing genes from its gene index. In addition, 
it has the option to operate through a graphical user interface, making it accessible to users without 
any programming knowledge and is freely available in GitHub as a Java application. 
(https://github.com/muxingu/rnamut). Users of RNAmut should be aware of its limitations such as 
the fact that it is not designed to detect copy number variations or indels longer than 30 bp other 
than FLT3-ITDs or MLL-PTDs, and as it relies on transcribed RNA it cannot identify intronic or 
intergenic SNVs. Furthermore, users of customized gene panels will need to ensure that their genes 
of interest are expressed sufficiently for RNAmut to detect any mutation, which is a general 
limitation of all RNA-seq based mutation callers.  
 
The current molecular diagnosis of AML relies on multidisciplinary workflows including cytogenetic, 
molecular and next-generation sequencing (NGS) tests in order to detect different types of 
mutations. In this study, we demonstrate that all diagnostically important somatic mutations in AML 
can be reliably detected from RNA-seq within one single workflow. Our bespoke software, RNAmut, 
greatly reduces the difficulty and time required to analyse NGS data with results that match or even 
out-perform current methods. As our approach can be readily combined with information such as 
gene expression and splicing from the same RNA-seq dataset, it can be used to generate integrated 
algorithms that enhance prognostication and patient treatment. Furthermore, as RNA sequencing is 
a relatively straightforward procedure, our approach can readily be taken up by the AML research 
community and also by clinical laboratories, for whom it can significantly reduce experimental costs 
and accelerate AML genomic diagnosis and classification. 
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Table 1: Genes and types of mutations detected by RNAmut.  
For MLL fusions the 8 most common partners were searched for. 
 
 
Table 1: 
Genes Hotspots Indel &SNV 
Tandem 
Duplication 
Gene Fusion 
NPM1 W288fs Yes   
FLT3 D835-D839 Yes FLT3-ITD  
IDH1 R132 Yes   
IDH2 R140, R172 Yes   
CEBPA  Yes   
TET2  Yes   
DNMT3A R882 Yes   
RUNX1  Yes   
TP53  Yes   
ASXL1  Yes   
WT1  Yes   
BCOR  Yes   
SRSF2  Yes   
SF3B1  Yes   
U2AF1  Yes   
KMT2A (MLL)   MLL-PTD MLL-partners 
PML    PML-RARA 
RARA    PML-RARA 
MYH11    MYH11-CBFB 
CBFB    MYH11-CBFB 
RUNX1T1    RUNX1-RUNX1T1 
BCR    BCR-ABL 
ABL1    BCR-ABL 
NUP98    NUP98-NSD1 
NSD1    NUP98-NSD1 
MLLT1    KMT2A-MLLT1 
AFF1 (MLLT2)    KMT2A-AFF1 
MLLT3    KMT2A-MLLT3 
AFDN (MLLT4)    KMT2A-AFDN 
EPS15 (MLLT5)    KMT2A-EPS15 
ELL    KMT2A-ELL 
MLLT10    KMT2A-MLLT10 
MLLT11    KMT2A-MLLT11 
 
  
Figure 1: Schematic depiction of the RNAmut pipeline.  
A) Pipeline flowchart. B-E) Summarized explanation of detection strategies for B) substitutions and 
small indels, C) tandem duplications, D) gene fusions using chimeric reads that capture the 
breakpoint and E) gene fusions using chimeric paired-end reads. Detailed explanations are given in 
the Supplementary Appendix. 
 
Figure 2: Assessment of our software’s accuracy against previously published annotations.  
Results of testing RNAmut against the 151 RNA-seq datasets from the AML cohort of TCGA. 
Mutations detected by both our software and Ley et al. 2013 are depicted in yellow, additional 
mutations detected only by our software in purple and the two mutations missed by our software 
but detected by Ley et al. 2013 in green. Mutations in SRSF2 (not called by Ley et al.) are omitted 
from the plot and are shown in Supplementary Data. The 3 samples with no mutations detected are 
not shown. Details of the specific mutations in individual samples are provided in Supplementary 
Data. 
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1 Algorithm Design
1.1 Transcript Indexing
To boost the alignment speed, transcript sequences of the 33 clinically rele-
vant genes (Table 1) to AML diagnosis were indexed prior to read alignment.
Transcript sequences of GRCh38 v93 were downloaded from the Ensembl
database [1]. Non-coding transcripts and the ones without Consensus CDS
annotations were excluded. For multiple protein-coding transcripts that only
differ in untranslated regions (UTRs), only the one with longest UTR was re-
tained. Along each transcript (including both sense and antisense sequences),
a sliding window of k -mers were used to compute the hash function that maps
each k -mer sequence to the isoform(s) and locus/loci that the k -mer belongs
to (Supplementary Figure 1A). The hash function allows for fast retrieval of
the genic loci for any given k -mer sequence with a time complexity of O(1).
The optimal k -mer size k = 10 was chosen, considering the balance between
memory usage and alignment speed (Supplementary Table 1).
k-mer Size
Probability of
Match by
Chance
Minimum
RAM
(MB)
Alignment
Speed
(sec/million
reads)
9 0.64 75 18.3
10 0.16 279 8.6
11 0.040 1022 7.2
12 0.010 3362 7.0
Supplementary Table 1: Performance of index using different k-mer
size. Memory usage was calculated on a 64-bit operating system. Alignment
speed were tested on a laptop with Intel Core i7 1.8-4.0 GHz Processor and solid
state hard drive and the average speed of 151 samples was shown. RAM = Random
access memory.
1.2 RNA-seq alignment
Single-end and paired-end reads were aligned with slight differences. Prior
to alignment, unknown nucleotides (N in FASTQ files) were trimmed from
5' and 3' ends of sequenced reads. Trimmed reads that are shorter than 40
bp were discarded. Each trimmed read was divided into consecutive k -mers.
If the read length is not a multiple of k -mer length, an overlapping k -mer is
added to the 3' end. Using the pre-built index, the transcript location(s) of
each k -mer were retrieved and assessed. A reads is considered unaligned if
4
fewer than N of the k -mers are mapped to the same transcript, where:
N = Max(2, [
1
2
· L
k
]) (1)
in which L is the length of the read and k is k -mer length which means that
at least half of the k -mers must be mapped to the same transcript (Supple-
mentary Figure 1). Poly-A or poly-T k -mers were considered as mapped to
the end of the transcript. In addition, every pair of mapped k -mers must
be in the correct order within the tolerated range of 30 bp of insertion or
deletion:
|(Ti − Tj)− (Ri −Rj)| 6 10 ∀ i, j and i 6= j (2)
where i and j are a pair of k -mers, T is the location of the k -mer on the
transcript and R is its location on the read. Reads that satisfy both criteria
were considered as aligned. An additional requirement must be met for
paired-end alignment - both 5' and 3' reads must be aligned to the same
transcript and the outer distance (i.e. fragment length) must be less or equal
to 1000 bp, which corresponds to the maximum DNA length in a typical
sequencing library.
k-mer
AAAAAAAAAA
......
GGGCGATGTC
......
GGCGATGTCC
......
GGGGGGGGG
Transcript:Loca�on
-
......
NPM1+: 0
......
NPM+1: 1, FLT3-:472
......
-
Hash Func�on
A
>NPM1 (+) 
GGGCGATGTCCTTGCTAATTTGGAGACTGATTCAGTCCCCTTTTGGCCCCC ... ...
k-mers
Transcript Indexing
>NPM1 (-)
ACCTGCAGCGCGAGGCGCGCCGCTCCAGGCGGCATCGCAGGGCTGGGC ... ...
ACTAGCAGCATCGATCGATCAGCACGACTGACTGACGCTAGCTACGACGT
CACCACTCCCCCCGCGCCACTGCATGGCGTGAGGGCAGCCCAGGTCTCCA
TET2+: 158 TET2+: 168 TET2+: 188 TET2+: 198
CACCACTCCCCCCGCGCCACTGCACGGCGTGAGGGCAGCCCAGGTCTCCA
TET2+: 158 TET2+: 168 TET2+: 188 TET2+: 198TET2+: 178
TACCCTGCTTTACACATTAATACCCTACCACAAGGAGAATACCTACTTTTTAT
FLT3+: 568 FLT3+: 578 FLT3+: 497 FLT3+: 507
CAAGTCTAAGTTTAAGACAGGGAAGTCTGACGACCAGCGGCAGCTGCAG
KMT2A+: 866 KMT2A+: 876 ELL+:1927 ELL+:1937
Unaligned (U)
Aligned (A)
Aligned (M)
Unaligned (U)
Unaligned (U)
B Single-end Read Alignment
Supplementary Figure 1: Transcript indexing. (A) Index was built by con-
structing the hash function that maps every k -mer within the transcript sequences
of the 33 target genes, including both sense (+) and antisense (-) strands, to its
location on the transcript. It is possible that a k -mer maps to multiple locations.
(B) Examples of read alignment by k -mer mapping. Reads were classified into
unaligned (type U), aligned with mismatches (type M) and perfectly aligned (type
A).
1.3 Detection of substitutions and small indels
From reads aligned to transcripts, the ones with imperfect alignment (i.e.
containing unmapped k -mer(s)) were selected for detection of substitutions
5
and small indels. For each unmapped region, the pair of mapped k -mer flank-
ing this region were used as anchors and matching bases between the read
and transcript were extended from the anchors into the unmapped region,
resulting in NT bases remaining on the transcript and NR bases remaining
on the read. If the unmapped region is located at the 5' or 3' end of read, the
extending process was done from one anchor only. The type of the mutation
could be identified by comparing NT and NR:
NT = 0 and NR > 1 Insertion
NT > 1 and NR = 0 Deletion
NT = 1 and NR = 1 Substitution
NT > 1 and NR > 1 Multiple
(3)
For the case that more than 1 bases are remaining in both the transcript
and the read, indicating the possibility of multiple mutations, the Needleman-
Wunsch algorithm (match score = 10, mismatch score = -8, gap open penalty
= -9, gap extension penalty = -2) was applied to find out the location mu-
tations (Supplementary Figure 2A). Reads that contain > 12 mismatches
or > 3 indels were discarded as unaligned. The locations of mutations on
transcripts were converted to genomic coordinates. If multiple genomic coor-
dinates can represent the same mutation, the one with the lowest coordinate
was used as the primary locus (Supplementary Figure 2A). A number of cri-
teria must be satisfied for mutation calling. The RNA-seq quality (Phred
Score) of the mutated base of substitutions, the average score of inserted
bases, or the average score of the two bases flanking the deletion site must
be > 20 (i.e. error 6 0.01). At least 5 reads with unique sequences have to
be covering the mutation site and the variant allele frequency (VAF), which
is defined as:
V AF =
Nmut
Nmut + Nwt
(4)
where Nmut and Nwt are the number of mutated and normal reads respec-
tively, must be > 0.05 for the mutation to be called in the initial round.
However, mutation calling was not attempted for mismatches within the
first and last 10 bp of reads to avoid false discovery because for example, it
is impossible to distinguish whether a 2-bp mismatch at the beginning of a
read is due to an insertion or two substitutions. Instead, these reads were
retained for realignment and VAF correction.
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...GAC CAAGAGGCTATTCAAGATCTCTGGCAGTGGAGGAAGCTCTTTAAGAAA...
CAAGAGGCTATTCAGGATCTCTGTCTGGCATTGGAGGAAGCTCTTTAAG
Gene
Read
...GAC CAAGAG CTATTCAA
CAAGAGGCTATTCAG
GTGGAGGAAGCTCTTTAAGAAA...
T TGGAGGAAGCTCTTTAAGGATCTCTGTCTGGCA
GATCTCTGGCA
A GATC------TCTGGCAG
GGATCTCTGTCTGGCAT
k-mer extension
Needleman-Wunsch
Detection of Substitutions & Small Indels
Mapped k-mer Unmapped k-mers Mapped k-mer 
A GATCT------CTGGCAG
A GATCTC------TGGCAG
A GATCTCT------GGCAG
A GATCTCTG------GCAG
Primary Locus
Secondary Loci
Gene (Mut)
Read
Duplication
Gene (WT)
k-mer extension
Duplication Coordinates
Gene (Mut)
Gene 1 Gene 2
Read
Gene 1 Gene 2
Break Point
k-mer 
extension
Gene 1
Paired
Reads
Gene 2
Detection of tandem duplication
Detection of gene fusion Detection of gene fusion
A B
C D
Supplementary Figure 2: Strategies for detection of various types of
mutations. (A) Substitutions and small indels, (B) tandem duplications, (C)
gene fusion using RNA-seq reads that span the breakpoint or chimeric reads, and
(D) gene fusion from paired-end reads that align to each of the fusion partners.
1.4 Detection of tandem duplication
From the pool of unaligned reads, the ones with both 5'- and 3'-end k -mers
mapped to the same transcript and the 3' k-mer is mapped upstream of the
5' k -mer, were flagged for potential tandem duplication. To reduce false
positive rate, at least one of the 5' or 3' end must contain > 2 consecutively
mapped k -mers for the call of tandem duplication to be attempted. From the
mapped 5' k -mer(s) towards downstream and 3' k -mer(s) towards upstream,
each matching bases between the read and transcript was used to extend
the matched region. The extension process terminates if either of the two
conditions is met. Firstly, if all bases in the read were covered, then the
coordinates of the duplicated region on the transcript could be obtained by
the first and last matched base on the transcript (Supplementary Figure
2B). Secondly, if both 5' and 3' extension reached a mismatching base and
nucleotides remained in the read, then this indicated that the remaining
nucleotides were inserted between the two duplicated regions. At least 5 reads
with unique sequences must cover a putative duplication site and the VAF
must be >0.05 for the tandem duplication to be called initially. Unaligned
reads containing at least 2 consecutive mapped k -mers only at one end were
retained for realignment and VAF correction.
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1.5 Detection of gene fusion
Reads whose 5' and 3' k -mers were mapped to each of the partners in a
fusion pair were flagged as putative chimeric reads. At least one of the 5'
or 3' end must contain > 2 consecutively mapped k -mers. Reads with only
one mapped k -mer at both 5' and 3' ends were retained for realignment.
Matching bases to the corresponding transcript were extended from both
ends until no bases remain in the read. Read with >1 bases remaining were
discarded. The coordinate of the breakpoint on each transcript was obtained
from the ends of the extension of 5' and 3' k -mers (Supplementary Figure
2C). At least 3 reads with unique sequences must cover the breakpoint for
a fusion to be called. For paired-end RNA-seq specifically, an independent
strategy was used by extracting the pairs in which each read were aligned
to one of the fusion partners (Supplementary Figure 2D). However, paired-
end read spanning the fusion partners do not reveal the coordinates of the
breakpoint.
1.6 Realignment and VAF correction
Realignment improves the VAF calculation by taking previously discarded
or ignored reads, which contain true positives, and aligning them to the
wild-type (WT ) and mutated sequences around the mutation site. Realign-
ments were attempted for each of the substitutions, small indels, tandem
duplications and gene fusions detected from chimeric reads but not for gene
fusions detected by paired-end reads. The maximum read length L was ob-
tained during the read alignment step. For substitutions and small indels,
mutated and WT sequences were constructed from the subsequence ±L bp
around mutation spot, including and excluding the mutated region respec-
tively (Supplementary Figure 3A, B). For tandem duplication, the mutated
sequence was constructed by joining L bp at the end and L bp at the be-
ginning of the duplicated region while the WT was constructed by ±L bp
around the end of the duplicated region (Supplementary Figure 3C). For gene
fusion, mutated sequence was constructed by joining L bp of the 5' transcript
upstream of the breakpoint and L bp of the 3' transcript downstream of the
breakpoint. Two WT sequences were constructed for gene fusion, each com-
posed of ±L bp around the breakpoint of their transcript (Supplementary
Figure 3D). For each mutation, a pair of new indices were built for the mu-
tated sequence and WT sequence(s) using the same algorithm as transcript
indexing (Supplementary Figure 1A). The new indices were used to realign
the reads that were retained for realignment (explained in previous sections).
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Realignment tolerates 6 2 mismatches, no insertion or deletion and no mis-
match within the mutated spot for both WT and mutated sequences. A read
will be marked as mutated or WT if it is exclusively aligned to the mutated
sequence or to the WT sequence respectively. The VAF values were updated
using the new Nmut and Nwt after realignment.
 D
Gene
Substitution /Insertion
Mut
WT
Gene Deletion
Mut
L
WT
Gene (Mut)
L
L
L
Duplication
Mut
L L
WT
2 eneG1 eneG
L LL L
L L
Mut
L L
WT1
WT2
A   
 B
 C
Supplementary Figure 3: Construction of mutated and WT sequence for
realignment. L denotes the maximum length of RNA-seq reads. (A)Substitution
and small insertion, (B) small deletion. (C) tandem duplication and (D) gene
fusion.
1.7 Flagging sequencing artefact
Insertions and deletions that are single-nucleotide long or consisting of ho-
mopolymers were check for possible sequencing artefacts. The sequence sur-
rounding the insertion or deletion sites were extracted. If the surrounding se-
quence consists of >4 nucleotides that are the same as the inserted or deleted
nucleotide(s), it will be flagged as a potential sequencing artefact. For exam-
ple, an insertion of A in a regions of AAAAAA will be flagged as artefact.
Sequencing artefacts will be reported but not checked for oncogenicity unless
explicitly stated in the oncogenicity filter.
1.8 Oncogenicity filter
After obtaining the mutations in an RNA-seq dataset, the next step was to
identify the oncogenic ones that are potential drivers and remove irrelevant
9
mutations such as single nucleotide polymorphisms (SNPs) and benign muta-
tions. We used the same criteria used by Papaemmanuil et al. 2016 [2], which
select for known hotspots, recurrent mutations in public databases [3, 4] and
mutations in functional domains. Gene fusions, FLT3 -ITD and MLL-PTD
were always retained. The criteria are summarized in Supplementary Table
2.
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Gene Included Mutations
NPM1 W288fs, W290fs
IDH1 R132
IDH2 R140, R172
FLT3 D835, D839, Y842C, N841,R834Q, V592, Y572,
DNMT3A R882, Frameshift, Stop-codon gain, F909, P904, W893, Q886,
N879, E863D, P849L, Q842H, T835M, K829, R803, N797K,
W795C, R792H, P777R, E774D, L773, R771Q, S770, F752,
F751L, R749C, R736, R729, P718R, V716D, S714, L713F,
G707, I705T, D702V, G699D, D686, S669F, A662G, R635Q,
W581, L547, G543, C497, K468
TP53 Frameshift, Stop-codon gain, R290H, E286, R283H, D281N,
P278S, A276P, C275, R273, V272M, R267, G266R, L265P,
G262V, E258A, I254V, R248, G245D, C242S, S241, N239D,
C238Y, M237, Y234, P223S, Y220, S215, Y205D, V203E,
P196Q, I195, H193, H179R, C176, R175H, V173L, H168P,
K164E, Y163C, G154D, V143M, T140N, F134I, K132R,
L130V, R110L, F109C, F54L, E11K
CEBPA Frameshift, Stop-codon gain, A.A.Insertion 300-302, L338P,
N321, V314A, Q312K, Q311K, E309, R306P, A303P, D301,
R300, R297, A295E, N293S,
TET2 Frameshift, Stop-codon gain, R1896T, T1884A, H1881R,
R1868Y, A1512V, R1467K, Q1445R, V1417F, H1417R, H1380,
G1370E, F1368V, R1359C, L1322Q, C1298W, G1282C, C1273,
A1264, R1262, R1261C, C1221, N1102, H949R, A665D, S460F,
E154V
RUNX1 Frameshift, Stop-codon gain, M267I, N260K, R250C, S226,
R207P, R204Q, R201, P200S, D198, K171N, G168R, S167N,
R166, G165, R162, D160Y, A149, S141, P113, R107, S100F,
S94I
WT1 Frameshift, Stop-codon gain,H465, D464, R462, R458P, R434,
R370P, R369G, G351R
BCOR Frameshift, Stop-codon gain,L1550, R1131L
ASXL1 Frameshift, Stop-codon gain, G646fs, K85R, P511S, A530V,
A772T, R786K, T787N, E801, V1060D
U2AF1 Frameshift, Stop-codon gain, R188H, Q157, R156, R35, S34,
R28
SRSF2 P95, A.A.Deletion 90-110, F57Y, Y44H
SF3B1 K700, K666, Frameshift, Stop-codon gain, A.A.Deletion 690-
710, D799G, D781G, E776D, R775L, A749T, G742D, G740,
I704N, V701F, A672V, H662, N626, R625, E622, S611F,
G605D,
Supplementary Table 2: Selection criteria for oncogenic mutations.
Known hotspots are colored in red.
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2 Supplementary Methods
2.1 Data acquisition
BAM files of the RNA-seq data of the 151 AML samples were downloaded
from the TCGA portal [5]. FASTQ files of the 437 RNA-seq data from
the Leucegene datasets [6, 7, 8, 9] were downloaded from Gene Expression
Omnibus [10] using the fastq-dump.2 in the SRA Toolkits [11]. RNA-seq
data and genotypes of the MDS cohort were obtained from the Ogawa and
Cazzola groups (unpublished data). Gene annotation, coding/non-coding
transcripts and CCDS sequences of the human assembly GRCh38 version 93
were downloaded from Ensembl database [1].
2.2 Bioinformatics analyses
RNA-seq data were mapped to the GRCh38 version 93 by STAR v2.7.0d [12]
using parameters --outFilterMismatchNoverReadLmax 0.05
--alignIntronMax 500000. Alignments were visualized by Interactive Ge-
nomics Viewer IGV [13].
For benchmarking read alignment, sequences of the 33 genes relevant to
AML diagnosis were indexed using BWA 0.7-17 [14] and RNA-seq samples
were aligned using BWA-MEM under default parameters. Reads with BWA
score higher than 95 (out of 100) were marked as aligned. The sequences were
also indexed by Salmon v0.13.1 [15] using -k 31 and aligned using default
parameters.
For quantification of Variant Allele Frequencies (VAFs), the pileup func-
tion of Samtools 1.9 [16] was used to calculate VAFs of substitutions, al-
lowing only bases with Phred33 score >20. Varscan v2.4.3 [17] was used
with Samtools mpileup to identify and calculate the VAFs of small indels
and substitutions, using default parameters. To detect gene fusions, a fusion
index was first built using FuSeq [18] with the default SQLite database of
GRCh37 version 75. FuSeq was run under default parameters to identify
gene fusions.
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3 Supplementary Results
3.1 Mutations detected by our software
To test the performance our software, we acquired the RNA-seq data from
three independent cohorts − the TCGA AML cohort of 151 patient samples,
the Leucegene AML datasets of 437 patients [8, 6, 9, 7], and an MDS cohort
of 164 patients [19].
We performed analyses on these 3 cohorts with the 33-gene panel and called
mutations within these genes. Mutation landscapes are summarized in this
section.
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3.1.1 TCGA and Leucegene show similar distributions of muta-
tions
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Supplementary Figure 4: Mutations detected by our software in TCGA
and Leucegene datasets. Our software identified similar distributions of muta-
tions in (A) the AML cohort of TCGA and (B) the Leucegene datases.
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3.1.2 Number of mutations in the MDS cohort
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3.1.3 Mutational landscape in Leucegene datasets
Leucegene - 391 patient samples
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Supplementary Figure 6: Landscape of mutations in the Leucegene
datasets. Only 391 of the 437 samples showing at least one mutations in the
tested genes are shown.
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3.1.4 Mutational landscape in the MDS dataset
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Supplementary Figure 7: Landscape of mutations in the MDS dataset.
Mutations detected by both our software and by Shiozawa et al. are depicted in
yellow, additional mutations detected only by our software in purple. Our software
detected all annotated mutations. Details of the mutations in individual samples
are given in Supplementary Data.
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3.1.5 Summary of detected FLT3 -ITDs in TCGA
All the FLT3 -ITD detected by our software are located between amino acid
590 and 630 (Supplementary Figure 8A) with length from 4 amino acid
upto 35 (Supplementary Figure 8B), which ares consistent with COSMIC
database. Our software also reports the allelic frequency of ITDs (Supple-
mentary Figure 8C), which could be useful for prognostic prediction.
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Supplementary Figure 8: Summary of detected FLT3 -ITDs. (A) Number
of FLT3 -ITD detected at each amino-acid position. (B) Distribution of lengths
of ITDs. (C) Distribution of VAFs (indication of ITD-to-WT ratio).
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3.2 Check for multiple mapping
3.2.1 Check for multiple mapping by exact match
Since our algorithm only focuses on 33 genes and ignores the rest of the
transcriptome, it is essential to confirm that RNA-seq reads produced from
the transcripts outside the 33 genes do not fortuitously align to our panel
genes. To test for this, we first generated the sequences of every L-bp win-
dows (for L = 30, 40, 50 and 75) on all the Ensembl coding and non-coding
transcripts other than these 33 genes (Supplementary Figure 9A). Genes that
are antisense to panel genes, such as MFSD11, NDE1 and CDC42SE1 were
excluded. We carried out string-matches for 30, 40, 50 and 75-bp windows
against the coding regions of 33 panel genes (i.e. excluding UTRs). For all
sizes of windows, we observed no sequence identity to the coding regions of
our 33-gene panel (Supplementary Figure 9B).
Sequence identity was observed in the UTRs of IDH 2 and SF3B1 for 30-
mers (unpublished data), which is due to repetitive sequences in the UTRs.
However, mutations in UTRs do not cause changes in protein product and
no recurrent diagnostically or prognostically important UTR mutations have
been reported in AML or MDS.
It is worth mentioning that the exact match does not simulate the RNA-
mut algorithm. Firstly, it only takes single-end reads as input, which are
much more likely to be mistakenly aligned than paired-end reads and hence
an overestimation of potential errors. On the other hand, this method toler-
ates no mismatches, which is an underestimation of real error rate.
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Supplementary Figure 9: Uniqueness of mapping for the subsequences
of panel genes. (A) Ensembl transcripts other than the 33 panel genes were
obtained. Subsequences were generated using a sliding window of 30, 40, 50 and
75 bps moving by 1 bp at a time. (B) Each window was searched against the
coding sequence of the 33 panel genes and the number of matches at each genic
position were plotted.
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3.2.2 Check for multiple mapping by simulation
To better simulate real RNA-seq data, we took all Ensembl transcripts other
than the 33 panel genes and also excluding antisense gene MFSD11, NDE1
and CDC42SE1. We first generated 300-bp fragments (i.e. typical size of
sequencing libraries) by sliding 1 bp at a time on the transcript. For each
fragment, we produced a pair of reads of a L bp from the two ends of the
fragment. This process was repeated with L = 30, 40, 50 and 75, producing
4 sets of simulated paired-end reads. Each set of simulated reads were passed
to the RNAmut alignment algorithm, using the default parameters.
For 30 bp, we observed reads from 1-3 non-panel genes mistakenly aligned to
SRSF2 and RUNX1, whereas for 40, 50 and 75-bp simulation, no reads were
aligned to the coding regions of panel genes. This indicates that a minimum
threshold of 40 bp of paired-end reads after end-clipping could be a good
choice of parameter.
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Supplementary Figure 10: Estimation of mapping errors by simulation.
(A) Generation of simulated reads. Protein-coding and non-coding transcripts
from the Ensembl database (other than the panel genes) were used. 300-bp frag-
ments were first generated using sliding windows and then paired-end reads were
generated from the two ends of the fragments. (B) Simulated reads were aligned
using RNAmut algorithm with default parameters. Numbers of simulated reads
aligned to the panel genes were plotted against coding-region positions.
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3.2.3 Distribution of read lengths
To establish the lengths or end-clipped reads in real data, we examined
the raw sequencing reads in TCGA, Leucegene and MDS cohorts. TCGA
datasets was sequenced before 2013 and the read lengths are typically 50 bp
whereas the other two cohorts are more recent and both of which are 100 bp.
The unknown nucleoties (N) were clipped from both ends of reads and the
lengths of the remaining reads were examined.
We observed that less than 1 percent of the reads were shorter than 40 bp
in the TCGA dataset, suggesting very little impact on the mutation-calling
results due to the small fraction (Supplementary Figure 11A, B). For modern
sequencing data, the effect is much less significant or non-existent.
0
20
40
60
80
100
0.0
0.2
0.4
0.6
0.8
1.0
Pe
rc
en
ta
ge
 o
f r
ea
ds
Pe
rc
en
ta
ge
 o
f r
ea
ds
≤ 3
0b
p
≤ 4
0b
p
≤ 5
0b
p
≤ 3
0b
p
≤ 4
0b
p
≤ 5
0b
p
≤ 7
5b
p
≤ 1
00
bp
≤ 3
0b
p
≤ 4
0b
p
≤ 5
0b
p
≤ 7
5b
p
≤ 1
00
bp
≤ 3
0b
p
≤ 4
0b
p
≤ 3
0b
p
≤ 4
0b
p
≤ 5
0b
p
≤ 3
0b
p
≤ 4
0b
p
≤ 5
0b
p
TCGA Leucegene MDS TCGA Leucegene MDSA B
N-clipped reads N-clipped reads
Supplementary Figure 11: Distribution of end-clipped read lengths. (A)
Distribution of the percentages or reads within 30, 40, 50, 75 and 100 bp in each
dataset. (B) Same as (A) but zoomed in on the low values.
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3.3 Software benchmarks
To validate each step of our pipeline, we compared our results with existing
bioinformatic tools. Read alignment was compared with the commonly used
aligners BWA [14], STAR [12] and Salmon [15]. For the purpose of bench-
marking, we chose BWA and Salmon for the panel-gene alignment (instead
of genome alignment), for closest resemblance to the RNAmut algorithm.
Furthermore, we also benchmarked the alignment of RNAmut to the whole-
genome alignment by STAR.
RNAmut’s quantification of single nucleotide variants (SNVs) was compared
with Samtools [16] and Varscan [17], indel detection was compared with
Varscan and gene fusion was compared with FuSeq [18].
3.3.1 Comparison between our software and BWA
Since our alignment is based on transcript sequence, the closest resemblance is
to the non-spliced aligner BWA. We constructed BWA index using transcript
sequences of 33 panel genes and aligned the RNA-seq reads to the transcripts.
The number of reads aligned by our software show very good agreement with
BWA (Supplementary Figure 12A). The common set of reads aligned by both
our software and BWA comprises approximately 95% of the reads aligned by
any one software (Supplementary Figure 12B), with the exception of IDH2
where the common set is ∼75% of the reads aligned by BWA, which is due
to our software aligned more reads than BWA in IDH2.
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Supplementary Figure 12: Comparison between read alignment by our
software and BWA. (A) Scatter plot of number of reads aligned to each gene
by our software versus those aligned by BWA for the 151 RNA-seq samples in
TCGA AML. Genes that are fusion partners were not included. (B) Fractions of
reads aligned by both (i.e. overlap) in reads aligned by BWA or our software. Bars
represent the mean of fractions of 151 samples and error bars show the standard
deviation.
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3.3.2 Comparison between our software and STAR
The spliced aligner STAR is the standard aligner for RNA-seq data. To per-
form STAR alignments, we first aligned RNA-seq reads to the entire genome.
Reads aligned to the panel genes were extracted using Samtools. Reads
aligned to the intronic regions were removed with customized scripts. We
also observed very good correlations between the number of reads aligned by
our software and STAR (Supplementary Figure 13).
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Supplementary Figure 13: Comparison between read alignment by our
software and STAR. Similar to Supplementary Figure 12A.
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3.3.3 Comparison between our software and Salmon
Salmon is another widely used aligner which aligns RNA-seq reads directly
to transcripts, which is also similar to RNAmut’s alignment in nature. To
compare with Salmon, we built the gene index using transcript sequences and
quantified number of reads aligned to each gene. The comparison shows very
good correlation between our software and Salmon (Supplementary Figure
15).
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Supplementary Figure 14: Comparison between read alignment by our
software and Salmon. Similar to Supplementary Figure 12A.
27
3.3.4 Our VAF calculation agrees with Samtools and Varscan
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Supplementary Figure 15: Comparison between VAFs calculated by
our software and (A) Samtools pileup, which only detects substitutions, (B)
Varscan for substitutions and (C) Varscan for indels.
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3.3.5 Our fusion detection agrees with and out-performs FuSeq
for MLL fusions
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2844 ELL
2834 ELL ELL
2883 MLLT4
2842 MLLT10 MLLT10
2893 MLLT4
2894 MLLT3
2911 ELL ELL
2956 MLLT3 MLLT3
2823 Y Y
2840 Y Y
2841 Y Y
2862 Y Y
2872 Y Y
2897 Y Y
2980 Y Y
2982 Y Y
2991 Y Y
2994 Y Y
2998 Y Y
2999 Y Y
3001 Y Y
3007 Y Y
3012 Y Y
2815 Y Y
2828 Y Y
2846 Y Y
2870 Y Y
2881 Y Y
2888 Y Y
2889 Y Y
2892 Y Y
2914 Y Y
2942 Y Y
2806 Y Y
2819 Y Y
2858 Y Y
2875 Y Y
2886 Y Y
2937 Y Y
2950 Y Y
2817 Y Y
2901 Y Y
2941 Y Y
2856 Y Y
2918 Y Y
2930 Y Y
Supplementary Table 3: Comparison between our software and FuSeq
for detecting gene fusions. Samples where a fusion is detected are indicated as
Y. For MLL-fusions, the fusion partner is shown in the box.
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3.4 RNA and DNA VAFs
3.4.1 Comparision between DNA and RNA VAFs
RNA VAF by our software
D
N
A 
VA
F 
by
 L
ey
 2
01
3
D835E
D835E
D835HD839G
FLT3
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
D835Y
Other R300C
CEBPA
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
R803S
Q515*
Q615*
K829R
Q485*
R729Q
R792H
R729W
C497Y
R320*
R736H
F909C
DNMT3A
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Other
R882X
R132H
R132H R132G
R132S
IDH1
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Other
R132C
R172K
R172K
R140L
IDH2
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Other
R140Q
R201*
D198N
S141L
R201*
R162G
R162K
R201*
R162S
R162G
R320*
R201Q
P113L
A149P
RUNX1
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
C176Y
S215G
H193Y
Q317*
R248Q
H179R
I195S
R273C
E286GTP53
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Q947*
Q481*
TET2
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
R462W
H465Y
WT1
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
K700E
SF3B1
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Q157P
S34F
S34F
S34Y
S34Y
S34F
S34F
U2AF1
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Supplementary Figure 16: Comparison of RNA VAF and DNA VAF
RNA VAFs were calculated by our software and DNA VAFs were obtained from
whole exome data by Ley et al. 2013 [20]. Only VAFs for substitutions are shown
since the software Ley et al. used did not report VAFs for indels or ITDs.
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3.4.2 VAFs of Putative Non-sense Mediated Decay Mutations
To test whether non-sense mediated decay can lead to RNAmut missing mu-
tations from RNA-seq data, we assessed the differences between DNA and
RNA VAFs. Since Ley et al. only reported DNA VAFs for gain-of-stop-
codon, but not for frameshift mutations, while our software reports both, we
only checked the correlation for stop-codon gains in 17 genes identified in the
TCGA dataset by Ley et al. 2013.
We constructed a new index for all these genes (as not all were included in our
33-gene panel) and then called mutations using RNAmut. RNAmut reported
23 mutations of stop-codon gains across these 17 genes. Comparison between
RNA and DNA VAFs shows roughly similar levels of RNA VAFs compared
to DNA VAFs (Supplementary Figure 17) and there was no evidence for con-
sistently lower values derived from RNA data. Pertinently, even in instances
with lower RNA VAFs mutations were easily detectable from RNA-seq data.
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Supplementary Figure 17: VAFs of potential non-sense mediated Decay.
RNA VAFs quantified by our software is plotted against DNA VAFs quantified by
Ley et al.
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3.5 The IDH1 mutation not detected by RNA-seq
In sample TCGA-AB-2984, our software failed to detect the IDH1 R132C
mutation that has been annotated from whole exome sequencing. We in-
spected the RNA-seq reads around the hotspot (chr2:208248389) and found
only one mutated reads aligned to the hotspot (Supplementary Figure 18).
A
B
C
D
E
F
IDH1
Sample: TCGA-AB-2984
Chr2
Supplementary Figure 18: RNA-seq reads of the sample TCGA-AB-
2984 around the IDH1 R132C hotspot. Only one read (A) with mutation
is found at this hotspot. Other reads (B-F) contain sequences outside the exon
of IDH1, which were not captured by our software. These reads may come from
genomic contamination of the RNA-seq library or RNA from retained introns.
3.6 Evidence for novel detections by our software
Our software detected mutations in 29 samples that were not previously
detected (23 SNVs/indels and 6 ITDs). In this section we provide evidence
of mutated reads in RNA-seq and where available whole exome sequencing
(WXS) data. Reads containing substitutions and small indels were visualized
in the IGV browser [13]. However, reads from tandem duplications cannot
be visualized by IGV because they are unaligned to the genome. Instead, we
listed all these reads in relation to the duplication junction to demonstrate
that our discoveries are true positives.
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3.6.1 Evidence for substitutions and small indels
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Supplementary Figure 19: Evidence for substitutions and small indels
detected by our software. IGV browser tracks showing evidence of mutated
reads for mutations detected by our software but not by previous studies. WXS
did not cover the N-terminal domain of CEBPA and is hence not shown.
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Supplementary Figure 20: Evidence for substitutions and small indels
detected by our software (continued).
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3.6.2 Evidence verifying newly detected FLT3 -ITDs
35
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SOLEXA2_0122:5:44:6116:16994/2_rev 
SOLEXA2_0122:5:114:14378:6841/1_rev 
SOLEXA3_0140:2:107:10471:8120/2_rev 
SOLEXA2_0122:5:15:9986:2873/1_rev 
SOLEXA2_0122:5:83:9208:2728/1 
SOLEXA3_0140:2:95:11038:8907/2 
SOLEXA2_0122:5:65:10632:17647/2_rev 
SOLEXA3_0140:2:1:2713:12414/1_rev 
SOLEXA2_0122:5:30:6131:8594/2 
SOLEXA2_0122:5:118:5265:3880/1 
SOLEXA2_0122:5:114:2478:8090/2 
SOLEXA2_0122:5:44:13892:15381/1 
SOLEXA2_0122:5:106:13030:19235/1 
SOLEXA3_0140:2:61:15216:6070/1_rev 
SOLEXA2_0122:5:115:4161:17442/1 
Sample: TCGA-AB-2823. ITD: chr13:28034110-28034181 
CTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCG 
CTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCG 
CTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCG 
CTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCG 
  ACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGC 
  ACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGC 
   CGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCT 
   CGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCT 
   CGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCT 
   CGTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCT 
    GTTGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTC 
      TGATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCT 
       GATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTC 
        ATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCA 
        ATTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCA 
         TTTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAG 
          TTCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGA 
           TCAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGAT 
            CAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATA 
            CAGAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATA 
              GAGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAAT 
               AGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATG 
               AGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATG 
               AGAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATG 
                GAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGA 
                GAATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGA 
                 AATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAG 
                  ATATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGT 
                   TATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTA 
                    ATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTAC 
                    ATGAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTAC 
 
SOLEXA2_0122:5:80:6414:11108/2 
SOLEXA2_0122:5:61:4349:8630/1 
SOLEXA2_0122:5:11:7640:16497/2_rev 
SOLEXA3_0140:2:16:11203:18013/2_rev 
SOLEXA2_0122:5:96:17043:6482/1_rev 
SOLEXA2_0122:5:94:4136:8911/2_rev 
SOLEXA3_0140:2:33:12050:1299/1_rev 
SOLEXA3_0140:2:11:6690:6934/1_rev 
SOLEXA2_0122:5:78:4403:10981/2 
SOLEXA3_0140:2:8:17467:5048/1 
SOLEXA2_0122:5:112:7686:4283/2 
SOLEXA2_0122:5:66:12294:12490/2 
SOLEXA3_0140:2:16:7145:9583/1 
SOLEXA3_0140:2:2:10228:13571/1 
SOLEXA2_0122:5:10:16344:8444/2_rev 
SOLEXA3_0140:2:96:14504:13549/2_rev 
SOLEXA2_0122:5:69:14521:4399/1 
SOLEXA3_0140:2:50:17297:17194/2 
SOLEXA3_0140:2:68:8131:7955/2_rev 
SOLEXA2_0122:5:19:10173:20348/1_rev 
SOLEXA2_0122:5:69:19022:13367/2 
SOLEXA3_0140:2:95:17951:11266/2 
SOLEXA2_0122:5:8:12908:14475/2 
SOLEXA3_0140:2:107:16869:21047/1_rev 
SOLEXA2_0122:5:102:13360:13586/1 
SOLEXA2_0122:5:62:8922:11669/2 
SOLEXA3_0140:2:83:1483:10977/2 
SOLEXA2_0122:5:49:12200:16639/2_rev 
SOLEXA3_0140:2:25:15935:20306/2_rev 
SOLEXA2_0122:5:66:4385:2883/2_rev 
SOLEXA2_0122:5:29:16750:18669/1 
                      GAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTT 
                      GAATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTT 
                       AATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTC 
                        ATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCT 
                        ATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCT 
                        ATATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCT 
                         TATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTA 
                         TATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTA 
                         TATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTA 
                          ATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTAC 
                          ATGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTAC 
                           TGATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACG 
                             ATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTT 
                             ATCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTT 
                              TCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTG 
                              TCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTG 
                              TCTCAAATGGCAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTG 
SOLEXA2_0122:5:94:17431:11642/2_rev 
SOLEXA2_0122:5:21:7896:1352/1 
SOLEXA2_0122:5:30:19116:10569/1_rev 
SOLEXA2_0122:5:106:18556:11097/2 
SOLEXA2_0122:5:20:15511:18616/1 
SOLEXA2_0122:5:98:18561:19697/2 
SOLEXA3_0140:2:25:11526:7594/1_rev 
SOLEXA2_0122:5:117:17000:2379/1_rev 
SOLEXA3_0140:2:20:4195:20209/1 
SOLEXA2_0122:5:103:3790:12210/1_rev 
SOLEXA2_0122:5:75:17171:16837/2_rev 
SOLEXA2_0122:5:104:9498:20453/1_rev 
SOLEXA2_0122:5:74:10757:4143/1 
SOLEXA2_0122:5:97:15064:7222/1_rev 
SOLEXA3_0140:2:11:12395:7414/2 
SOLEXA2_0122:5:89:13262:13107/2_rev 
SOLEXA2_0122:5:77:5473:11938/1_rev 
Sample: TCGA-AB-2862. ITD: chr13:28034092-28034160 
AATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTAC 
AATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTAC 
 ATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACT 
 ATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACT 
 ATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACT 
  TATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTT 
  TATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTT 
    TGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCT 
    TGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCT 
    TGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCT 
     GAATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTA 
      AATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTAC 
       ATATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACG 
        TATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGT 
        TATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGT 
         ATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTT 
         ATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTT 
         ATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTT 
         ATGATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTT 
           GATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGA 
           GATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGA 
           GATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGA 
            ATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGAT 
            ATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGAT 
            ATCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGAT 
             TCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATT 
             TCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATT 
             TCTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATT 
              CTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTT 
              CTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTT 
              CTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTT 
              CTCAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTT 
                CAAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCA 
                 AAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAG 
                 AAATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAG 
                  AATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGA 
                  AATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGA 
                  AATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGA 
                   ATGGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAG 
                     GGGAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAA 
                       GAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATA 
                       GAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATA 
                       GAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATA 
                       GAGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATA 
                        AGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATAT 
                        AGTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATAT 
                         GTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATG 
                         GTTTCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATG 
                            TCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAAT 
                            TCCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAAT 
                             CCAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATA 
                              CAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATAT 
                              CAAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATAT 
                               AAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG 
                               AAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG 
                               AAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG 
                               AAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG 
                               AAGAGAAAAT AATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG 
 
SOLEXA11_36:3:27:18519:17314/2_rev 
SOLEXA3_1:3:53:17417:16056/2 
SOLEXA11_36:3:39:4909:1819/1 
SOLEXA3_1:3:71:5826:12224/1_rev 
SOLEXA3_1:3:35:6804:14524/2 
SOLEXA3_1:3:53:10971:21048/2_rev 
SOLEXA3_1:3:110:16954:18768/2 
SOLEXA11_36:3:106:9357:17783/2 
SOLEXA11_36:3:16:7662:7097/2 
SOLEXA3_1:3:22:10902:17961/2 
SOLEXA3_1:3:86:12306:4162/2 
SOLEXA3_1:3:51:15104:5838/1_rev 
SOLEXA11_36:3:113:19754:8438/1 
SOLEXA11_36:3:120:3459:7168/1 
SOLEXA3_1:3:53:14102:20288/2 
SOLEXA11_36:3:49:16159:15010/2 
SOLEXA3_1:3:91:2159:9380/1_rev 
SOLEXA3_1:3:11:3455:14590/1_rev 
SOLEXA11_36:3:99:11129:4928/2_rev 
SOLEXA3_1:3:49:10730:17663/1 
SOLEXA3_1:3:24:18866:2661/1 
SOLEXA3_1:3:117:14611:7288/2_rev 
SOLEXA3_1:3:66:14854:13036/2 
SOLEXA3_1:3:88:12347:18143/1 
SOLEXA3_1:3:116:6612:10612/2_rev 
SOLEXA3_1:3:32:7949:5753/2 
SOLEXA3_1:3:25:17864:17692/2 
SOLEXA3_1:3:91:2659:18446/2_rev 
SOLEXA3_1:3:17:18954:15359/1_rev 
SOLEXA11_36:3:78:5408:15527/1_rev 
SOLEXA11_36:3:45:9883:2754/1 
SOLEXA11_36:3:80:5563:17900/2 
SOLEXA11_36:3:77:9073:5114/2 
SOLEXA11_36:3:115:3710:18448/2 
SOLEXA11_36:3:10:11854:3359/1_rev 
SOLEXA3_1:3:13:7141:11843/2 
SOLEXA3_1:3:69:18702:19224/2_rev 
SOLEXA3_1:3:104:19559:15512/2_rev 
SOLEXA11_36:3:23:12139:6894/2 
SOLEXA3_1:3:72:15152:18501/2 
SOLEXA3_1:3:58:11596:19239/2_rev 
SOLEXA3_1:3:83:16234:9463/2_rev 
SOLEXA3_1:3:26:17972:3509/2_rev 
SOLEXA3_1:3:47:14127:12110/1_rev 
SOLEXA3_1:3:21:3247:11838/1 
SOLEXA3_1:3:43:5396:13133/2 
SOLEXA3_1:3:51:18644:16202/1 
SOLEXA11_36:3:105:18088:15980/2_rev 
SOLEXA3_1:3:1:19757:11326/1 
SOLEXA3_1:3:93:18580:15300/1 
SOLEXA3_1:3:102:1391:13581/1_rev 
SOLEXA3_1:3:45:12308:20158/2 
SOLEXA3_1:3:87:12038:8680/1 
SOLEXA3_1:3:99:17451:14629/2 
SOLEXA3_1:3:93:13743:7527/1_rev 
SOLEXA11_36:3:3:13637:15990/1_rev 
SOLEXA11_36:3:88:8606:4535/2_rev 
SOLEXA11_36:3:86:18747:9194/1 
Sample: TCGA-AB-2896. ITD: chr13:28033977-28034129 
AGTTTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATAT 
AGTTTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATAT 
AGTTTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATAT 
 GTTTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATG 
   TTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGAT 
   TTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGAT 
   TTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGAT 
   TTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGAT 
   TTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGAT 
   TTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGAT 
     CCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCT 
     CCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCT 
     CCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCT 
      CAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTC 
        AGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAA 
        AGAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAA 
         GAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAA 
         GAGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAA 
          AGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAAT 
          AGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAAT 
          AGAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAAT 
           GAAAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATG 
             AAATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGG 
              AATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGA 
              AATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGA 
               ATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAG 
               ATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAG 
               ATTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAG 
                TTTAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGT 
                  TAGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTT 
                   AGAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTC 
                    GAGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCC 
                     AGTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCA 
                      GTTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAA 
                       TTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAG 
                       TTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAG 
                       TTTGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAG 
                         TGGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAG 
                          GGGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGA 
                           GGAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAA 
                            GAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAA 
                            GAAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAA 
                             AAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAA 
                             AAGGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAA 
                               GGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATT 
                               GGTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATT 
                                GTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTT 
                                GTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTT 
                                GTACTAGGAT ATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTT 
 
SOLEXA12_58:1:114:12269:8993/1 
SOLEXA4_149:1:117:5999:8336/2 
SOLEXA12_58:1:90:18506:12471/2_rev 
SOLEXA12_58:1:103:6068:16212/2_rev 
SOLEXA4_149:1:109:19604:8542/1_rev 
SOLEXA4_149:1:109:11537:7087/2_rev 
SOLEXA4_149:1:28:15392:16387/2 
SOLEXA12_58:1:35:6385:9888/1_rev 
SOLEXA4_149:1:107:15576:16617/2 
SOLEXA4_149:1:85:2343:15374/2_rev 
SOLEXA4_149:1:107:15931:15766/2_rev 
SOLEXA12_58:1:75:16524:7340/2_rev 
SOLEXA12_58:1:63:16102:15939/2_rev 
SOLEXA4_149:1:39:5807:13905/1 
SOLEXA12_58:1:9:11588:12896/2 
SOLEXA4_149:1:48:4380:14677/2 
SOLEXA4_149:1:88:13271:12734/1 
SOLEXA12_58:1:84:4925:4650/2 
SOLEXA12_58:1:50:4393:9289/2 
SOLEXA12_58:1:67:6852:18637/2_rev 
SOLEXA4_149:1:2:10667:3835/1 
SOLEXA4_149:1:5:1716:14595/1_rev 
SOLEXA4_149:1:7:18239:18652/1_rev 
SOLEXA4_149:1:11:15809:14905/1 
SOLEXA12_58:1:99:7464:8444/2 
SOLEXA4_149:1:14:15013:13519/2 
SOLEXA12_58:1:57:16667:1054/1_rev 
SOLEXA12_58:1:25:14579:20820/1 
SOLEXA12_58:1:78:15478:5622/1_rev 
SOLEXA4_149:1:57:8153:7113/2_rev 
SOLEXA12_58:1:28:6811:19346/1 
SOLEXA12_58:1:6:16396:4124/2_rev 
SOLEXA12_58:1:72:7172:1822/1 
SOLEXA4_149:1:62:5210:9561/2_rev 
SOLEXA12_58:1:23:15037:18044/1_rev 
SOLEXA4_149:1:84:2758:1953/2_rev 
SOLEXA12_58:1:114:9933:5703/2_rev 
SOLEXA12_58:1:20:13587:18020/1 
SOLEXA12_58:1:59:10497:18090/1 
SOLEXA12_58:1:119:7873:4064/2_rev 
SOLEXA12_58:1:75:7636:20621/1_rev 
SOLEXA4_149:1:33:6060:18719/2 
SOLEXA4_149:1:118:1962:12296/2 
SOLEXA12_58:1:94:18233:1164/2_rev 
SOLEXA12_58:1:84:10613:21191/1 
SOLEXA12_58:1:120:8684:17277/1 
SOLEXA4_149:1:59:9742:9916/1 
SOLEXA4_149:1:106:5233:15507/2 
SOLEXA4_149:1:43:3986:3447/1_rev 
Sample: TCGA-AB-2919. ITD: chr13:28034089-28034181 
TATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGAC 
   GAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGG 
   GAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGG 
    AATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGC 
     ATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCT 
          ATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCA 
          ATCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCA 
           TCTCAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAG 
              CAAATGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATA 
                  TGGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGA 
                   GGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAG 
                   GGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAG 
                   GGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAG 
                   GGGAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAG 
                     GAGTTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTA 
                        TTTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTT 
                         TTCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTC 
                          TCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCT 
                          TCCAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCT 
                            CAAGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCTAC 
                              AGAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGT 
                               GAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTT 
                               GAGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTT 
                                AGAAAATTTACAG GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTG 
 
SOLEXA5_0118:1:40:18858:5550/2_rev 
SOLEXA5_0118:1:35:4531:1282/2_rev 
SOLEXA12_0040:1:52:3014:15735/2_rev 
SOLEXA12_0040:1:45:4733:20061/2_rev 
SOLEXA5_0118:1:6:2243:11816/2 
SOLEXA12_0040:1:113:4260:13180/1 
SOLEXA5_0118:1:42:9391:1276/1_rev 
SOLEXA12_0040:1:94:12111:11907/2 
SOLEXA5_0118:1:53:1989:3388/1 
SOLEXA5_0118:1:92:9541:20109/2 
SOLEXA5_0118:1:36:15359:19269/1_rev 
SOLEXA5_0118:1:109:13373:4132/2_rev 
SOLEXA5_0118:1:27:16351:9243/2 
SOLEXA12_0040:1:67:2587:18062/1_rev 
SOLEXA12_0040:1:94:17983:12467/1 
SOLEXA12_0040:1:42:4106:18929/1_rev 
SOLEXA12_0040:1:52:12860:2241/1 
SOLEXA12_0040:1:88:13237:11394/1_rev 
SOLEXA12_0040:1:110:11565:14616/2_rev 
SOLEXA5_0118:1:8:4272:16930/2_rev 
SOLEXA5_0118:1:113:17446:16533/1 
SOLEXA5_0118:1:75:7417:12288/2 
SOLEXA12_0040:1:107:11445:14961/2_rev 
SOLEXA5_0118:1:39:10777:17140/1 
Sample: TCGA-AB-2949. ITD: chr13:28034107-28034133 
TACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAA 
 ACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAAC 
 ACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAAC 
 ACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAAC 
  CGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACG 
  CGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACG 
   GTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGG 
   GTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGG 
   GTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
    TTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG 
     TGATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG G 
      GATTTCAGAGAATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GA 
                AATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATAT 
                 ATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATG 
                 ATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATG 
                 ATATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATG 
                  TATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGA 
                  TATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGA 
                   ATGAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGAT 
                     GAATATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGATCT 
                         ATGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGATCTCAAA 
                          TGATCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGATCTCAAAT 
                             TCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGATCTCAAATGGG 
                             TCTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGATCTCAAATGGG 
                              CTCAAATGGGAGGTTC TAAACGGG GAATATGAATATGATCTCAAATGGGA 
 
SOLEXA9_0091:4:98:3784:8637/1 
SOLEXA5_0130:5:101:14036:6855/2_rev 
SOLEXA9_0091:4:43:17511:5629/1_rev 
SOLEXA5_0130:5:39:8643:2114/2_rev 
SOLEXA9_0091:4:81:14696:6484/1 
SOLEXA9_0091:4:65:5733:4103/2 
SOLEXA9_0091:4:61:10276:6831/1 
SOLEXA9_0091:4:1:6967:6956/1 
SOLEXA5_0130:5:69:15019:12956/1 
SOLEXA9_0091:4:108:16681:9419/1_rev 
SOLEXA5_0130:5:119:8419:21145/2_rev 
SOLEXA9_0091:4:52:17085:3583/2_rev 
SOLEXA9_0091:4:75:9093:6798/1_rev 
SOLEXA9_0091:4:95:18577:18319/2_rev 
SOLEXA5_0130:5:20:8565:11445/2_rev 
SOLEXA9_0091:4:72:5326:18262/2_rev 
SOLEXA5_0130:5:9:7432:3537/2_rev 
SOLEXA9_0091:4:114:4644:4715/1_rev 
SOLEXA5_0130:5:30:19752:10644/1_rev 
SOLEXA9_0091:4:71:18543:3122/2_rev 
SOLEXA5_0130:5:39:12664:4695/1_rev 
SOLEXA5_0130:5:119:10052:1170/1_rev 
SOLEXA9_0091:4:17:6852:8672/1_rev 
SOLEXA9_0091:4:81:18701:4349/2 
SOLEXA9_0091:4:89:15952:5951/1_rev 
SOLEXA5_0130:5:90:3701:3700/1 
SOLEXA5_0130:5:4:6102:15149/1 
SOLEXA9_0091:4:108:9803:3480/1 
SOLEXA9_0091:4:80:5806:9294/1_rev 
SOLEXA5_0130:5:51:11432:9755/1_rev 
SOLEXA9_0091:4:28:11884:5506/1 
SOLEXA5_0130:5:34:19443:2860/2 
SOLEXA5_0130:5:14:4020:17847/2_rev 
SOLEXA9_0091:4:116:16189:16806/2 
 
Supplementary Table 4: RNA-seq reads originated from the duplication junc-
tions are listed for each FLT3 -ITD detected by our software. Junctions consist
of the end of duplicated sequence (DupEnd) followed by the start of the dupli-
cated sequence (DupStart). In some cases, one or more nucleotides are inserted in
between.
4 Supplementary data
Excel sheets for all detected mutations in the TCGA AML and MDS cohorts,
and Leucegene datasets are provided in a separate file.
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